Pulmonary exacerbations in CF patients with early lung disease

Journal of Cystic Fibrosis

Volumn 13, Issue 1, 2014, Pages 74-79

  Anstead, Michael ^a   Saiman, Lisa ^b   Mayer Hamblett, Nicole ^c   Lands, Larry C ^d   Kloster, Margaret ^c   Goss, Christopher H ^c   Rose, Lynn ^e   Burns, Jane L ^f   Marshall, Bruce ^g   Ratjen, Felix ^h,i  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

^g Cystic Fibrosis Foundation   (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Azithromycin; Chronic; Cystic fibrosis; Infection; Lung function; Mild; Pseudomonas aeruginosa; Pulmonary exacerbation; Weight

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BURKHOLDERIA CEPACIA; CHILD; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION; LUNG WEIGHT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OXYGEN SATURATION; PHYSICAL DISEASE BY BODY FUNCTION; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; WEIGHT REDUCTION;

AZITHROMYCIN; CHRONIC; CYSTIC FIBROSIS; INFECTION; LUNG FUNCTION; MILD; PSEUDOMONAS AERUGINOSA; PULMONARY EXACERBATION; WEIGHT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; COUGH; CYSTIC FIBROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG; LUNG DISEASES; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 84890389448     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.07.006     Document Type: Article

References (28)

1. Goss C.H., Burns J.L. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax Apr 2007, 62(4):360-367. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review].
2. Stenbit A.E., Flume P.A. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med Nov 2011, 17(6):442-447. [Review].
3. Lieu T.A., Ray G.T., Farmer G., Shay G.F. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics Jun 1999, 103(6):e72.
4. Britto M.T., Kotagal U.R., Hornung R.W., Atherton H.D., Tsevat J., Wilmott R.W. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest Jan 2002, 121(1):64-72.
5. Hegarty M., Macdonald J., Watter P., Wilson C. Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions. Child Care Health Dev Jul 2009, 35(4):462-468. [Comparative Study].
6. Sanders D.B., Bittner R.C., Rosenfeld M., Redding G.J., Goss C.H. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol Apr 2011, 46(4):393-400. [Research Support, Non-U.S. Gov't].
7. Sanders D.B., Hoffman L.R., Emerson J., Gibson R.L., Rosenfeld M., Redding G.J., et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol Feb 2010, 45(2):127-134. [Research Support, Non-U.S. Gov't].
8. Davis S.D., Brody A.S., Emond M.J., Brumback L.C., Rosenfeld M. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc Aug 1 2007, 4(4):418-430. [Research Support, N.I.H., Extramural Review].
9. Vandevanter D.R., Yegin A., Morgan W.J., Millar S.J., Pasta D.J., Konstan M.W. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros 2011 Dec, 10(6):453-459.
10. Kraynack N.C., Gothard M.D., Falletta L.M., McBride J.T. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol Sep 2011, 46(9):870-881. [Research Support, Non-U.S. Gov't].
11. Sanders D.B., Hoffman L.R., Emerson J., Gibson R.L., Rosenfeld M., Redding G.J., et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010 Feb, 45(2):127-134.
12. Sanders D.B., Bittner R.C., Rosenfeld M., Redding G.J., Goss C.H. Pulmonary exacerbations are associated with subsequent FEV(1) decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011 Apr, 46(4):393-400.
13. Rosenfeld M., Emerson J., Williams-Warren J., Pepe M., Smith A., Montgomery A.B., et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr Sep 2001, 139(3):359-365.
14. Mayer-Hamblett N., Kronmal R.A., Gibson R.L., Rosenfeld M., Retsch-Bogart G., Treggiari M.M., et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol Feb 2012, 47(2):125-134. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
15. Byrnes C.A., Vidmar S., Cheney J.L., Carlin J.B., Armstrong D.S., Cooper P.J., et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5years of age. Thorax 2013 Jul, 68(7):643-651.
16. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med Sep 1 2010, 182(5):627-632. [Research Support, Non-U.S. Gov't].
17. Saiman L., Anstead M., Mayer-Hamblett N., Lands L.C., Kloster M., Hocevar-Trnka J., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA May 5 2010, 303(17):1707-1715. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
18. Treggiari M.M., Rosenfeld M., Mayer-Hamblett N., Retsch-Bogart G., Gibson R.L., Williams J., et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009 May, 30(3):256-268.
19. Anstead M., Saiman L., Mayer-Hamblett N., Lands L.C., Kloster M., Goss C.H., et al. Pulmonary exacerbations in patients 6-18years old with CF and mild lung disease uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 2010, 45(S33):440. [Abstract].
20. Treggiari M.M., Bendjelid K., Yanez N.D., Heidegger C.P., Suter P.M., Romand J.A. Atrial and brain natriuretic peptide concentrations and the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. J Crit Care Mar 2010, 25(1):23-29. [Research Support, Non-U.S. Gov't].
21. Sawicki G.S., Sellers D.E., Robinson W.M. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage Apr 2008, 35(4):372-380. [Research Support, N.I.H., Extramural].
22. Abbott J., Holt A., Hart A., Morton A.M., MacDougall L., Pogson M., et al. What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. J Cyst Fibros Sep 2009, 8(5):356-359.
23. Rabin H.R., Butler S.M., Wohl M.E., Geller D.E., Colin A.A., Schidlow D.V., et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol May 2004, 37(5):400-406.
24. Waters V., Stanojevic S., Atenafu E.G., Lu A., Yau Y., Tullis E., et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J Dec 1 2011.
25. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med Sep 2011, 165(9):847-856. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
26. Ratjen F., Saiman L., Mayer-Hamblett N., Lands L.C., Kloster M., Thompson V., et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest Nov 2012, 142(5):1259-1266. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
27. Davidson A.G., Chilvers M.A., Lillquist Y.P. Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic. Curr Opin Pulm Med Nov 2012, 18(6):615-621.
28. Amin R., Lam M., Dupuis A., Ratjen F. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr Pulmonol Jun 2011, 46(6):554-558. [Research Support, Non-U.S. Gov't].